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Abstract
Background: Patients with hematological malignancies are 
at increased risk for various infections. In patients with 
solid cancer, a variety of immunosuppressive mechanisms 
affecting T-cell response are described. We hypothesized that 
patients with advanced solid tumors may exhibit an impaired 
recognition of viral antigens. To test this, the capability of 
CD8+ T cells to recognize recall antigens from influenza and 
vaccinia virus was compared in patients and healthy indivi-
duals. Since all patients and most of the healthy individuals 
had been vaccinated against vaccinia years ago, comparison 
of the two groups was expected to be especially informative 
with respect to distinct effector T-cell reactivity. 
Materials and Methods: Our test population included 16 
healthy individuals and 12 patients with advanced solid 
cancers who were currently not receiving chemotherapy. We 
stimulated peripheral blood mononuclear cells (PBMC) ex 
vivo with the well-characterized influenza A matrix 58–66 
peptide and the immunogenic and HLA-A*0201 restricted 
peptide epitope SLSAYIIRV derived from the modified 
vaccinia virus Ankara (MVA). A specific CD8+ T-cell reactivity 
was determined by quantitative real-time polymerase chain 
reaction (qRT-PCR) measuring changes in interferon gamma 
(IFN-γ) mRNA expression levels. 
Results: We found that significantly fewer cancer patients 
than healthy individuals exhibited specific T-cell recognition 
of the vaccinia epitope (25% and 69%, respectively). In 
addition,  strength of the T-cell responses against both viral  
peptides was significantly reduced in  cancer patients.
Conclusion: Patients with advanced tumors are less likely 
to mount a T-cell response against viral epitopes. These 
findings may have implications for the design of immuno-
therapeutic interventions against virus-induced diseases, 
including tumors.  
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Introduction
Vaccines and other immunotherapies hold great promise 
as treatments for viral diseases and cancer, but are pre-
mised on the patient’s ability to mount an appropriate T-
cell response to a specific antigen. A vast amount of viral- 
and tumor-derived antigens have been identified that are 
recognized by cytotoxic T lymphocytes (CTL) in a major 
histocompatibility complex (MHC) class I restricted fa-
shion [1–5]. In contrast, little is known about the frequency 
and function of antigen-specific CD8+ T cells in selective 
patient populations, information that might be critical for 
the development of immunotherapeutic regimens.
In an attempt to determine CTL reactivity in patients 
and healthy individuals, we characterized the antigen-spe-
cific CD8+ T-cell response against epitopes from two viral 
model antigens, influenza and vaccinia [2, 6]. In adults, 
repeated exposure to influenza results in stimulation of 
the virus-specific memory and naive CTL precursor reper-
toire [1, 7]. In contrast, vaccination with modified vaccinia 
virus strains decades ago supposedly induced a life-long 
protective immune response provided by long-lasting and 
virus-specific CTL memory [8, 9]. HLA-A*0201-restricted 
CTL responses have been identified for both model viral 
antigens. For influenza, healthy individuals and patients 
with advanced cancer show a CTL response against the 
matrix peptide 58–66 [2, 3, 10, 11]. A recently identified 
immunogenic epitope derived from modified MVA, allows 
for direct monitoring of specific CD8+ T-cell responses in-
duced by different vaccinia virus strains [6, 12–14].
Patients with hematological malignancies are at incre-
ased risk for various infections [15, 16]. In patients with 
solid cancer, a variety of immunosuppressive mechanisms 
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affecting T-cell response systemically and in the tumor mi-
lieu are described [17, 18]. Therefore, we hypothesized that 
effector T cells from peripheral blood of cancer patients 
are less likely to mount an efficient response against the 
two viral recall antigens than T cells from healthy donors. 
Upon stimulation with an antigenic peptide epitope, CD8+ 
T cells generate the cytokine Interferon gamma (IFN-γ) 
[17, 18]. Here, we quantified this response in healthy indi-
viduals and in cancer patients by measuring IFN-γ mRNA 
expression following stimulation with antigenic peptides 
derived from influenza and vaccinia virus. 
Materials and Methods
Patients
Inclusion criteria included the presence of HLA-A*0201 MHC 
class I genotype, as determined by sequence-specific primer PCR 
(Protrans GmbH, Ketsch, Germany). Blood samples were obtai-
ned after informed consent. 16 healthy individuals, all health-care 
workers aged 27–60 years (mean 40 years), and 12 cancer patients 
(age 33–77 years, mean 58 years) were recruited. All patients were 
suffering from locally advanced and metastatic disease; in particu-
lar, two patients each suffered from solid cancers of the lung, co-
lon, pancreas, breast, and oropharynx, one patient had renal cell 
cancer, and another had liposarcoma. None of the cancer patients 
had received systemic chemotherapy or immunotherapy within 4 
weeks prior to examination of T cell reactivity. Detailed patient 
characteristics are shown in table 1. According to the detailed and 
reliable medical history, 13 healthy volunteers and all 12 patients 
had received the smallpox vaccination once in their lifetime (Ta-
ble 1). The time since the last smallpox vaccination was 7–38 years 
(mean 31 years, median 33 years). The donors were not tested for 
antibodies to influenza A since almost all individuals are seropo-
sitive due to previous exposure. Current influenza vaccines con-
sist of surface antigens such as hemagglutinin and neuraminidase; 
thus, they do not induce T-cell reactivity against the conserved 
matrix peptide from influenza A virus. Vaccination status of the 
individuals tested was therefore not relevant. 
Stimulation of Cytotoxic T Lymphocytes 
Peripheral blood mononuclear cells (PBMC) were isolated from 
heparinized blood by Ficoll-Hypaque density gradient centrifuga-
tion (Pharmacia Biotech, Uppsala, Sweden). For ex vivo stimula-
tion the vaccinia virus-derived epitope SLSAYIIRV which is pres -
ent in different vaccine strains was used [6, 14]. T-cell reactivity 
against influenza A virus was determined using the matrix peptide 
58–66 GILGFVFTL [2]. Reactivity to this antigen is demonstra-
ted in most individuals representing the individual memory T cell 
reactivation with respect to annual exposure [4, 10, 19–23]. All 
peptides were generated with standard solid phase chemistry on 
a multiple peptide synthesizer and analyzed by mass spectrome-
try [90% purity shown by high-pressure liquid chromatograhy 
(HPLC)], as described [23]. 
Autologous PBMC displaying vaccinia- and influenza-derived 
candidate peptides and a non-immunogenic control peptide (also 
not binding to HLA-A2) were used to expand specific CTL pre-
cursors from patients and healthy individuals as previously descri-
bed [23–25]. Briefly, ~2 X 106 PBMCs were pulsed with the appro-
priate peptide (5 µg/ml) and incubated for 1 h at 37 °C in X-VIVO 
10 medium (BioWhitaker, Gagny, France) supplemented with 
3 µg/ml 2-microglobulin, recombinant IL-7 (10 ng/ml) and 
IL-2 (10 U/ml) (R&D, Wiesbaden, Germany). One restimu-
lation was performed after 1 week (day 8) with the appropri-
ate peptide at the same concentration without adding cytoki-
nes. To obtain the highest IFN-γ mRNA yield, 2 X 106 PBMCs 
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Healthy  Age Smallpox                     Age       Smallpox
individuals     Gender  (years)     vaccination       Patients      Gender (years)    vaccination Cancer  TNM Stage
HD1  f 40 - P1 f 44 + Breast T4N1M1 IV
HD2 m 29 + P2 m 33 + HN T4N2M1 IV
HD3 m 27 - P3 m 56 + Lung T2N3M1 IV
HD4 f 35 + P4 f 70 + Breast T4N3M1 IV
HD5 f 46 + P5 f 60 + Lung T4N2M1 IV
HD6 f 60 + P6 m 53 + HN T2N1M1 IV
HD7 m 34 + P7 m 65 + Colon T3N2M1 IV
HD8 m 56 + P8 m 77 + Pancreas T3N1M1 IV
HD9 m 38 + P9 m 59 + RCC T4NxM1 IV
HD10 m 30 + P10 m 57 + Pancreas T2N1M1 IV
HD11 f 36 + P11 f 57 + Colon T2N1M1 IV
HD12 f 38 - P12 m 71 + LS T4NxM1 IV
HD13 f 38 +       
HD14 f 51 +       
HD15 f 53 +       
HD16 m 34 +
TNM staging of all patients with metastatic cancer (stage IV) at the time of evaluation was performed according to the updated 6th edition 
of the American Joint Committee on Cancer 2002 Cancer Staging Manual. Individuals who had received vaccinia vaccination (at least) once 
in their lifetime: +, those without vaccination: -; RCC: the patient with renal cell cancer; HN: head and neck cancer; LS: liposarcoma; f: 
female; m: male.   
Table 1
Characteristics of patients and healthy volunteers.      
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Figure 1. Assessment of immune reactivity for the influenza A peptide58–66 and the smallpox peptide with the TaqMan qRT-PCR in 16 healthy 
donors (HD) and 12 patients (P). Reactivity is displayed as the mean IFN-γ/CD8 ratio ± SD of healthy donors against the influenza matrix pep-
tide (H-flu) and the vaccinia peptide (H-po). Results are demonstrated for the patient (p-flu; p-po) group (according to individuals and con-
ditions a scatter graph is inserted). For characteristics of all individuals and clinical data of the cancer patients please refer to table 1 and the 
Materials and Methods section. IFN-γ/CD8 ratios were assessed as well after exposure to the irrelevant control peptide from a subset of ten 
individuals; mean values were calculated for all negative controls as indicated.
stimulation with HLA class I-presented epitope defines CD8+ 
T cells as the only relevant population, mRNA copy numbers 
were corrected for CD8 mRNA copies from the same sample 
creating a ratio that reflects the status of CD8+ T cell activation 
[3, 4, 20, 23]. This method of mRNA cytokine analysis after ex 
vivo exposure to viral or tumor peptides represents a simple and 
sensitive alternative to other methods that test epitope-induced 
T-lymphocyte reactivation for identifying immune dominant epi-
topes and investigation of clinically relevant T-cell responses [26]. 
Negative control IFN-γ/CD8 ratios (baseline ratios) were assessed 
for the irrelevant peptide AHTKDGFNF previously shown not to 
bind to HLA-A2 and not to be immunogenic [5, 23]. To determine 
the baseline ratios, T-cell reactivity against this irrelevant peptide 
was analyzed; the mean results of ten individual donors tested 
served as baseline. A positive response was defined as one greater 
than three standard deviations above background. All assays were 
performed in triplicate. Quantitative PCR results are displayed as 
CD8-normalized IFN-γ levels (IFN-γ/CD8 ratio ± SD). 
Statistics
The Kruskal-Wallis test was used for non-parametric compari-
sons of multiple groups. The Mann-Whitney test was used for 
were harvested 2 h after the last peptide-triggered restimulation 
[3, 4] and used immediately for RNA extraction and cDNA syn-
thesis [20, 23]. 
Real-Time Quantitative PCR
RNA (1 µg) was reverse-transcribed using oligo-p(dT)15 priming 
and avian myeloblastosis virus (AMV) reverse transcriptase (1st 
Strand cDNA Synthesis Kit for RT-PCR [AMV], [Roche Mole-
cular Biochemicals – RMB; GmbH, Mannheim, Germany] at 42 
°C for 1 h. Gene expression was measured with the ABI Prism 
7700 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA). PCR amplifications were carried out in tripli-
cate. Primer sequences for IFN-γ and CD8 were as follows: IFN-
γ (forward) 5’-AGCTCTGCATCGTTTTGGGTT-3’, IFN-γ (re-
verse) 5’-GTTCCATTATCCGCTACATCTGAA-3’; CD8 (for-
ward) 5’-CCCTGAGCAACTCCATCATGT-3’, CD8 (reverse) 
5’-GTGGGCTTCGCTGGC-3’. Corresponding TaqMan probes 
were used as described [3, 20]. DNA standards were generated 
by PCR amplification of gene products, purification, and quan-
tification by spectrophotometry (absorbance at 260 nm); stan-
dard curves were generated for both IFN-γ and CD8 and allow-
ed for extrapolation of the corresponding copy numbers. Since 
comparisons between groups, the Wilcoxon signed rank test for 
comparisons within the groups. The 2 test was used to compare 
the frequency of T cell reactivity between groups.
Results
Quantitative PCR Assessment of Peptide-
Specific Reactivity
We defined reactivity as the IFN-γ/CD8 ratio of ex vivo 
expanded peptide-specific precursors. Reactivity was 
monitored as changes in IFN-γ gene expression as deter-
mined by real-time qPCR [5, 20, 23, 26]. Significant reac-
tivity against the vaccinia virus peptide was demonstrated 
in 69% of the vaccinated healthy individuals (9/13), but 
in only 25% of the patients (P2, P6, and P8). Frequency 
of T-cell reactivity significantly differed between healthy 
individuals and patients (2 p < 0.027). Similar results for 
CD8+ T cell response were obtained in a cohort of 306 
healthy vaccine recipients 20–75 years after vaccination, 
substantiating our findings [27]. The strength of T cell 
reactivity against the vaccinia peptide in the entire co-
hort of cancer patients was significantly lower than was 
observed in healthy individuals (cancer patients: mean ± 
SEM was 0.23 ± 0.04, median 0.19; and healthy donors: 
mean ± SEM was 0.53 ± 0.12, median 0.36, respectively; 
Wilcoxon signed rank test p < 0.05). Two healthy do-
nors had received a booster vaccination against smallpox 
9 years (HD 6) and 7 years (HD 11) prior to the study. 
Surprisingly, they did not reveal any reactivity against the 
vaccinia peptide as compared to the irrelevant control 
peptide [8].
A significant increase in IFN-γ/CD8 ratio upon stimu-
lation with the influenza matrix peptide was demonstrated 
in 13 of 16 healthy donors (81%) and seven of 12 patients 
(58%), respectively (Figure 1) (frequency of T-cell reactiv-
ity p = 0.1841). Except for patient 9 (P9), who had previ-
ously undergone resection of a primary metastatic renal 
cell cancer, the average increase of IFN-γ /CD8 ratio was 
significantly higher in healthy individuals as compared to 
cancer patients (healthy donors: the mean ± SEM was 1.08 
± 0.2, median 0.92 and cancer patients: mean 0.53 ± 0.16, 
median 0.315, respectively; Mann-Whitney test p < 0.008). 
Ratios for IFN-γ/CD8 copies were 4.5 and 2.2 times, re-
spectively, above baseline indicating that ex vivo kinetics of 
the virus-specific effector T-cell repertoire and the corre-
sponding functional state are comparable to data obtained 
from tetramer-guided sorting and in vitro studies in hu-
mans [26–30]. We also found an increased reactivity (in-
dicated as IFN-γ/CD8 ratio) against the influenza peptide 
in comparison to that against the vaccinia peptide in both 
healthy individuals and cancer patients (p = 0.0082 and 
p = 0.0093, respectively).
Discussion
The importance of a strong and specific CD8+ T cell re-
sponse has become increasingly evident for the control of 
viral infection and tumor [1, 31, 32]. Alterations in cell-
mediated immune function are associated with frequent 
bacterial and viral infections; in cancer patients, however, 
lack of efficient T cell responses against viral pathogens is 
mainly reported in patients with hematological malignan-
cies [15, 16, 31, 33, 34]. Here we examined the reactivity 
against viral epitopes of influenza and vaccinia in patients 
with advanced solid tumors. 
We found that the frequency of immune response 
to the vaccinia epitope was significantly lower in cancer 
patients than in healthy individuals (25% vs 69%, respec-
tively). Also, strength of the specific T-cell response was 
significantly impaired in cancer patients when compared 
to the group of healthy individuals. These results suggest 
that advanced solid cancer may negatively influence spe-
cific CTL responses. However, frequency for recognition 
of the influenza virus epitope was similar in the group of 
healthy individuals and cancer patients. It is therefore con-
ceivable that cancer patients maintain their ability to re-
act to recall antigens like influenza A matrix to which they 
might be exposed repeatedly during the annual influenza 
season. Strength of the T cell reactivity against the influenza 
A epitope again was significantly lower in cancer patients, 
indicating that the recognition of both the vaccinia and the 
influenza antigen may be impaired by immunosuppressive 
conditions with respect to tumor burden and progression of 
disease, a reduced T cell repertoire or disrupted time frame 
for T cell recovery [15, 16, 35]. The increase in the CD8 nor-
malized T cell reactivity may appear moderate but is signifi-
cant and in line with other representative studies [26–30].
Of note, in all individuals tested the strength of T cell 
reactivity against the antigenic influenza peptide was signi-
ficantly higher than against the vaccinia antigen; a superior 
T cell reactivity that may be due to boosting and expansion 
of a virus-specific memory and naive CTL precursor reper-
toire [31, 36].
Unexpectedly, the two healthy volunteers who had 
received a smallpox booster 7 and 9 years previously did 
not exhibit an enhanced T cell reactivity against this im-
munogenic peptide. Whether this observation may be 
due to a potential disproportionate loss of specific CD8+ 
T cells early after boosting remains unclear [27, 36].
Results of this pilot study require validation in pros-
pective clinical trials also involving a greater number of 
individuals and complementary techniques such as tetra-
mer staining, ELISPOT and chromium release assays [26, 
37]. It should also be stressed that we have not evaluated 
other shared modes of protective immunity such as CD4+ 
T cell response and serum antibody levels [31, 36]. 
In conclusion, frequency and strength of the CD8+ 
T cell reactivity to the vaccinia epitope seemed to be im-
paired in cancer patients. Nonetheless, it appears that can-
cer patients maintain the ability to mount a specific T cell 
reactivity against viral epitopes. Whether quantification 
of T cell reactivity against antigens will serve as surrogate 
marker for monitoring in therapeutic and experimental 
vaccination settings needs to be explored.
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